1. Home
  2. DXC vs ANIP Comparison

DXC vs ANIP Comparison

Compare DXC & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DXC Technology Company

DXC

DXC Technology Company

HOLD

Current Price

$15.20

Market Cap

2.3B

Sector

Technology

ML Signal

HOLD

ANIP

ANI Pharmaceuticals Inc.

HOLD

Current Price

$81.84

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DXC
ANIP
Founded
1959
2001
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.0B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
DXC
ANIP
Price
$15.20
$81.84
Analyst Decision
Hold
Strong Buy
Analyst Count
7
6
Target Price
$15.33
$107.33
AVG Volume (30 Days)
2.2M
548.1K
Earning Date
01-29-2026
02-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
2.32
1.67
Revenue
$12,683,000,000.00
$826,880,000.00
Revenue This Year
N/A
$44.35
Revenue Next Year
N/A
$11.13
P/E Ratio
$6.11
$48.66
Revenue Growth
N/A
48.87
52 Week Low
$11.82
$54.10
52 Week High
$23.75
$99.50

Technical Indicators

Market Signals
Indicator
DXC
ANIP
Relative Strength Index (RSI) 49.62 49.82
Support Level $13.41 $78.79
Resistance Level $15.50 $83.80
Average True Range (ATR) 0.76 2.63
MACD -0.07 -0.11
Stochastic Oscillator 67.70 41.54

Price Performance

Historical Comparison
DXC
ANIP

About DXC DXC Technology Company

DXC Technology Co is a vendor-independent IT services provider. The company's operating segment includes Global Business Services (GBS) and Global Infrastructure Services (GIS). It generates maximum revenue from the GIS segment. GIS offerings include Cloud and Security; IT Outsourcing and Modern Workplace. Geographically, it derives a majority of revenue from the Other Europe region.

About ANIP ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

Share on Social Networks: